LLT-BMT1

LLT-BMT1 is an investigational **drug-eluting contact lens** being developed by **MediPrint Ophthalmics** for the treatment of **glaucoma** and **ocular hypertension**. The product is a **3D printed, sustained-release ophthalmic combination device-drug product** that incorporates **bimatoprost** and **hyaluronic acid** into a contact lens matrix using MediPrint's proprietary printing process. Its intended therapeutic effect is sustained lowering of intraocular pressure through local ocular delivery of bimatoprost, a prostaglandin analog that increases aqueous humor outflow, while the lens format enables continuous wear and prolonged drug exposure over approximately seven days.

Other names

bimatoprost drug-eluting contact lensbimatoprost and hyaluronic acid drug-eluting contact lens